Genetic breakthrough in medicine: an analysis of Exa-cel, the first FDA-approved CRISPR treatment for sickle cell disease
OA Version
Citation
Abstract
Sickle Cell Disease (SCD) is a genetic blood disorder characterized by the production of abnormal hemoglobin, the protein in red blood cells that carries oxygen throughout the body. This abnormal hemoglobin causes red blood cells to become rigid, sticky, and shaped like sickles or crescent moons. These misshapen cells can become stuck in small blood vessels, blocking blood flow, which leads to pain, infections, acute anemic episodes, and damage to body tissues. The disease is inherited when a child receives two sickle cell genes—one from each parent. The U.S. Food and Drug Administration (FDA) approved the first ever Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) treatment for sickle cell disease. Clustered Regularly Interspaced Short Palindromic Repeats is a technology used to selectively modify the DNA of living organisms. Exa-cel, also known by the brand name Casgevy, uses cutting-edge CRISPR gene editing technology to edit the BCL11A gene, which normally stops the body from producing a type of hemoglobin that is exclusive to fetuses. By editing the DNA of BCL11A, Cas9 deactivates the protein in bone marrow stem cells, which results in red blood cells with a typical round shape and fetal hemoglobin. This novel treatment involves removing the patient's own bone marrow stem cells, editing with exa-cel, followed by destroying the remaining, untreated bone marrow, and injecting the edited cells back into the patient. This breakthrough technique may provide patients with a long-term solution by not only addressing the underlying genetic defect and mitigating the symptoms of sickle cell disease. The study explores the progress of the treatment’s advancement, from research to clinical trials for evaluating the safety and effectiveness of the treatment, Exa-cel seems to be the most current gene therapy advancement in this fast-changing technological area. An in-depth assessment of the safety record of Exa-cel is compared to an analysis of treatment options like hydroxyureas therapy and stem cell transplants to highlight the benefits of Exa-cel treatment approach over others in both the short- and long-term periods. Additionally exploring how Exa-cel affects patients’ quality of life with a focus, on their reported experiences and daily life enhancements as considering issues related to accessibility and cost. Looking ahead to the possibilities of Exа-cеl’s role in genetic medicine innovation stands out as a breakthrough with the potential not just to revolutionize SCD care standards but also to drive progress in addressing various genetic conditions – paving the way for hopeful outcomes, for patients and the wider medical field.
Description
2025